Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Silverback Therapeutics patents TGFR-1 inhibitors

Feb. 11, 2021

Panbela provides updates regarding its development of SBP-101

Feb. 11, 2021

MGTA-117 confers better survival in preclinical models of AML

Feb. 11, 2021

VDA-1102 studied in new phase II trial for early forms of cutaneous T-cell lymphoma

Feb. 10, 2021

Basilea reports cohort 1 data from phase II study of derazantinib in intrahepatic cholangiocarcinoma

Feb. 10, 2021

Phase III study of napabucasin in metastatic colorectal cancer misses primary endpoints

Feb. 10, 2021

U.S. researchers divulge new immunotherapeutic constructs for cancer

Feb. 10, 2021

Shouyao Holdings (Beijing) identifies new Ret inhibitors

Feb. 10, 2021

Teon Therapeutics patents new adenosine A2A receptor antagonists

Feb. 10, 2021

NSC-765690 and NSC-765599 show antitumor activity against NCI60 human tumor cell lines

Feb. 10, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...